Progyny (NASDAQ:PGNY) Price Target Raised to $25.00 at Bank of America

Progyny (NASDAQ:PGNY) had its target price lifted by analysts at Bank of America from $21.00 to $25.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s price objective indicates a potential upside of 10.62% from the stock’s current price.

Other analysts also recently issued reports about the company. Truist Financial reissued a “hold” rating and issued a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Barclays lowered their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. JPMorgan Chase & Co. increased their price objective on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Canaccord Genuity Group reduced their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $25.83.

Progyny Stock Performance

PGNY stock opened at $22.60 on Tuesday. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $42.08. The company’s 50 day moving average price is $18.47 and its 200 day moving average price is $18.86. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of 38.58, a PEG ratio of 2.18 and a beta of 1.34.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same period last year, the business posted $0.16 EPS. Progyny’s revenue was up 2.0% on a year-over-year basis. Equities analysts forecast that Progyny will post 0.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, CEO Peter Anevski acquired 209,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were acquired at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman David J. Schlanger bought 150,000 shares of Progyny stock in a transaction that occurred on Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the transaction, the chairman now directly owns 228,269 shares of the company’s stock, valued at $3,350,988.92. This trade represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Progyny

A number of institutional investors have recently bought and sold shares of PGNY. Signaturefd LLC boosted its holdings in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after purchasing an additional 1,355 shares during the last quarter. Royce & Associates LP acquired a new position in Progyny in the fourth quarter valued at $339,000. First Eagle Investment Management LLC purchased a new stake in Progyny during the fourth quarter valued at about $2,500,000. River Road Asset Management LLC purchased a new position in shares of Progyny in the 4th quarter worth about $25,529,000. Finally, Amundi acquired a new position in shares of Progyny in the 4th quarter valued at about $102,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.